Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

A Longitudinal Study of Ebola Sequelae in Liberia.

PREVAIL III Study Group, Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, Moses SJ, Johnson KL, Gayedyu-Dennis D, Hensley LE, Higgs ES, Nath A, Tuznik K, Varughese J, Jensen KS, Dighero-Kemp B, Neaton JD, Lane HC, Fallah MP.

N Engl J Med. 2019 Mar 7;380(10):924-934. doi: 10.1056/NEJMoa1805435.

2.

Ebola Virus Isolation Using Huh-7 Cells has Methodological Advantages and Similar Sensitivity to Isolation Using Other Cell Types and Suckling BALB/c Laboratory Mice.

Logue J, Vargas Licona W, Cooper TK, Reeder B, Byrum R, Qin J, Deiuliis Murphy N, Cong Y, Bonilla A, Sword J, Weaver W, Kocher G, Olinger GG, Jahrling PB, Hensley LE, Bennett RS.

Viruses. 2019 Feb 16;11(2). pii: E161. doi: 10.3390/v11020161.

3.

PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.

Bolay FK, Grandits G, Lane HC, Kennedy SB, Johnson MP, Fallah MP, Wilson B, Njoh WS, McNay LA, Hensley LE, Higgs ES.

J Infect Dis. 2019 Apr 19;219(10):1634-1641. doi: 10.1093/infdis/jiy698.

PMID:
30561672
4.

Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans.

Cross RW, Speranza E, Borisevich V, Widen SG, Wood TG, Shim RS, Adams RD, Gerhardt DM, Bennett RS, Honko AN, Johnson JC, Hensley LE, Geisbert TW, Connor JH.

J Infect Dis. 2018 Nov 22;218(suppl_5):S486-S495. doi: 10.1093/infdis/jiy455.

5.

New Insights Into Marburg Virus Disease Pathogenesis in the Rhesus Macaque Model.

Cooper TK, Sword J, Johnson JC, Bonilla A, Hart R, Liu DX, Bernbaum JG, Cooper K, Jahrling PB, Hensley LE.

J Infect Dis. 2018 Nov 22;218(suppl_5):S423-S433. doi: 10.1093/infdis/jiy367.

PMID:
30053050
6.

In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus.

Dyall J, Johnson JC, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Michelotti J, Honko AN, Kern S, DeWald LE, O'Loughlin KG, Green CE, Mirsalis JC, Bennett RS, Olinger GG Jr, Jahrling PB, Hensley LE.

J Infect Dis. 2018 Nov 22;218(suppl_5):S592-S596. doi: 10.1093/infdis/jiy345.

PMID:
30016444
7.

Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate.

Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN, Oberlander N, Byrum R, Ragland D, St Claire M, Janosko KB, Smith G, Glenn G, Hooper J, Dye J, Pal S, Bishop-Lilly KA, Hamilton T, Frey K, Bollinger L, Wada J, Wu H, Jiao JA, Olinger GG, Gunn B, Alter G, Khurana S, Hensley LE, Sullivan E, Jahrling PB.

J Infect Dis. 2018 Nov 22;218(suppl_5):S636-S648. doi: 10.1093/infdis/jiy377.

8.

The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease.

DeWald LE, Dyall J, Sword JM, Torzewski L, Zhou H, Postnikova E, Kollins E, Alexander I, Gross R, Cong Y, Gerhardt DM, Johnson RF, Olinger GG Jr, Holbrook MR, Hensley LE, Jahrling PB.

J Infect Dis. 2018 Nov 22;218(suppl_5):S588-S591. doi: 10.1093/infdis/jiy332.

PMID:
29982632
9.

Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures.

Dyall J, Nelson EA, DeWald LE, Guha R, Hart BJ, Zhou H, Postnikova E, Logue J, Vargas WM, Gross R, Michelotti J, Deiuliis N, Bennett RS, Crozier I, Holbrook MR, Morris PJ, Klumpp-Thomas C, McKnight C, Mierzwa T, Shinn P, Glass PJ, Johansen LM, Jahrling PB, Hensley LE, Olinger GG Jr, Thomas C, White JM.

J Infect Dis. 2018 Nov 22;218(suppl_5):S672-S678. doi: 10.1093/infdis/jiy304.

PMID:
29939303
10.

Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates.

Smith DR, Johnston SC, Piper A, Botto M, Donnelly G, Shamblin J, Albariño CG, Hensley LE, Schmaljohn C, Nichol ST, Bird BH.

PLoS Negl Trop Dis. 2018 May 9;12(5):e0006474. doi: 10.1371/journal.pntd.0006474. eCollection 2018 May.

11.

Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs.

Postnikova E, Cong Y, DeWald LE, Dyall J, Yu S, Hart BJ, Zhou H, Gross R, Logue J, Cai Y, Deiuliis N, Michelotti J, Honko AN, Bennett RS, Holbrook MR, Olinger GG, Hensley LE, Jahrling PB.

PLoS One. 2018 Mar 22;13(3):e0194880. doi: 10.1371/journal.pone.0194880. eCollection 2018.

12.

MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells.

Cong Y, Hart BJ, Gross R, Zhou H, Frieman M, Bollinger L, Wada J, Hensley LE, Jahrling PB, Dyall J, Holbrook MR.

PLoS One. 2018 Mar 22;13(3):e0194868. doi: 10.1371/journal.pone.0194868. eCollection 2018.

13.

Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.

Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Sarro YDS, Pettitt J, Stavale EJ, Fallah M, Olinger GG, Bolay FK, Hensley LE.

J Virol Methods. 2018 May;255:84-90. doi: 10.1016/j.jviromet.2018.02.018. Epub 2018 Feb 23.

14.

Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.

Rimoin AW, Lu K, Bramble MS, Steffen I, Doshi RH, Hoff NA, Mukadi P, Nicholson BP, Alfonso VH, Olinger G, Sinai C, Yamamoto LK, Ramirez CM, Okitolonda Wemakoy E, Kebela Illunga B, Pettitt J, Logue J, Bennett RS, Jahrling P, Heymann DL, Piot P, Muyembe-Tamfum JJ, Hensley LE, Simmons G.

J Infect Dis. 2018 Jan 4;217(2):223-231. doi: 10.1093/infdis/jix584.

15.

Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG Jr, Hensley LE, Frieman MB, Jahrling PB.

Drugs. 2017 Dec;77(18):1935-1966. doi: 10.1007/s40265-017-0830-1. Review.

16.

Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.

Higgs ES, Dubey SA, Coller BAG, Simon JK, Bollinger L, Sorenson RA, Wilson B, Nason MC, Hensley LE.

Curr Top Microbiol Immunol. 2017;411:229-261. doi: 10.1007/82_2017_53.

PMID:
28918539
17.

Varicella Coinfection in Patients with Active Monkeypox in the Democratic Republic of the Congo.

Hoff NA, Morier DS, Kisalu NK, Johnston SC, Doshi RH, Hensley LE, Okitolonda-Wemakoy E, Muyembe-Tamfum JJ, Lloyd-Smith JO, Rimoin AW.

Ecohealth. 2017 Sep;14(3):564-574. doi: 10.1007/s10393-017-1266-5. Epub 2017 Sep 11.

PMID:
28894977
18.

High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona.

Honko AN, Johnson JC, Marchand JS, Huzella L, Adams RD, Oberlander N, Torzewski LM, Bennett RS, Hensley LE, Jahrling PB, Olinger GG.

Sci Rep. 2017 Jul 19;7(1):5886. doi: 10.1038/s41598-017-06179-y.

19.

Nonhuman Primate Models of Ebola Virus Disease.

Bennett RS, Huzella LM, Jahrling PB, Bollinger L, Olinger GG Jr, Hensley LE.

Curr Top Microbiol Immunol. 2017;411:171-193. doi: 10.1007/82_2017_20.

PMID:
28643203
20.

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.

Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG Jr, White JM.

PLoS Negl Trop Dis. 2017 Apr 12;11(4):e0005540. doi: 10.1371/journal.pntd.0005540. eCollection 2017 Apr.

Supplemental Content

Loading ...
Support Center